Turtlemint reports 38% revenue growth in H1 FY27

Turtlemint Fintech Solutions Limited announced its financial results for the half-year ended September 30, 2026 (H1 FY27). The company reported a significant 38% year-over-year growth in Revenue from Operations, reaching INR 637 crore. Service EBITDA also saw a substantial increase of 66% YoY to INR 85 crore, indicating improved profitability. Platform premium grew by 52% YoY to INR 2,419 crore.

Turtlemint Reports Strong H1 FY27 Performance

Turtlemint Fintech Solutions Limited has released its financial results for the first half of the fiscal year 2027 (H1 FY27), ending September 30, 2026. The company demonstrated robust growth across key performance indicators, highlighting a strong operational and financial period.

Key Financial Highlights for H1 FY27:

  • Platform Premium: Increased by 52% YoY to INR 2,419 crore.
  • Revenue from Operations: Grew by 38% YoY to INR 637 crore.
  • Service EBITDA: Saw a substantial rise of 66% YoY to INR 85 crore.
  • Policies Issued: Totaled 3.4 million.
  • Digital Partners: Recruited 69,000+ new Digital Partners in H1 FY27, reaching a total of 728,138.
  • Insurer Partners: Collaborates with 46 insurer partners.
  • B30+ Market Penetration: Continues to secure 76%+ premium from B30+ markets.

Q2 FY27 Performance Snapshot

In the second quarter of FY27 (Q2 FY27), Turtlemint also showed positive momentum:

  • Platform Premium: Increased by 55% YoY to INR 1,214 crore.
  • Revenue from Operations: Grew by 35% YoY to INR 342 crore.
  • Renewal Revenue: Increased by 41% YoY to INR 71 crore.
  • Service EBITDA Margin: Maintained a stable 13% margin YoY.
  • DPs Recruited: Added 37,000 DPs.
  • Quarterly Active DPs: Reached over 93,000.

The company’s strategy continues to focus on expanding its digital partner base, particularly in B30+ markets, and leveraging its technology platform to drive growth and enhance customer and partner experiences.

Source: BSE

Previous Article

B.N. Rathi Securities Ltd. reports ₹428.58 crore profit for Q2 FY27

Next Article

Asston Pharmaceuticals approves unaudited financial results for H1 FY27